---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-014073"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:19:09.239336+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants

## Summary
- Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.
- Gross proceeds ~$2.2M; H.C. Wainwright acted as placement agent (7% fee).
- Company issued new unregistered Series C (2,424,998 shares, 5-yr term) and Series D (2,424,998 shares, 18-mo term) warrants at $0.915.
- New warrants exercisable only after stockholder approval; proceeds for working capital and product development.

## SEC filing metadata
- accession: 0001493152-25-014073
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315225014073/0001493152-25-014073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315225014073/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-014073
- JSON: https://secwatch.observer/filing/0001493152-25-014073.json
- Plain text: https://secwatch.observer/filing/0001493152-25-014073.txt

## Key facts
- Equity Issuances
  Enveric Biosciences, Inc. issued up to 2,424,998 shares of Common Stock of warrant to certain institutional investors (the "Holders") for aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees.
  - Security: warrant
  - Shares: up to 2,424,998 shares of Common Stock
  - Purchaser: certain institutional investors (the "Holders")
  - Consideration: aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees
  source text: (the “New Series D Warrant Shares” and, together with the New Series C Warrant Shares, the “New Warrant Shares.”) The Company received aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees and other offering expenses payable by the Company. The Company engaged H.C.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315225014073/0001493152-25-014073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.